How does Myriad conduct BART testing?
- 1 people answered
Edit Tags
Tags are used to find the best answers
You might also be interested in
It depends on the country. Overdiagnosis relates to the finding of a cancer that doesn’t act in a life-limiting way. Since the beginning of mammography and PSA eras we have diagnosed a lot of such disease.Mammography has not changed the percentage of women who have metastatic disease, rather it has ....
As you know, chemotherapy, radiation and surgery, along with targeted treatments, gene therapy, laser and a few others are the standard traditional procedures for cancer treatment; they are called that because they have a proven track record and you can look up research results and find out that tho....
The risk is so low that it is impossible to read using tables of published health data and statistics. Children do get cancer, but very rarely breast cancer. Statistics will often group women aged 15–39 as “young women” but this is very misleading as the bump in cases begins in women over 20, or eve....
Credihealth is not a medical practitioner and does not provide medical advice. You should consult your doctor or with a healthcare professional before starting any diet, exercise, supplementation or medication program. Know More
كُتب بواسطة:Dr. Nitika Sharma - BDS
تمت مراجعته من قبل:Dr. Rakesh Kumar - MBBS, MS
Mahima Chaudhary
Imagine going in for a cancer screening, and the technician turns to you and says, "We're finished, but if I push this button over here, the machine can detect even smaller cancers. But here's the hitch: You have to pay $700 if you want me to push this button."
Myriad Genetics is doing something very similar with BART tests that determine if a woman has a potentially dangerous genetic abnormality linked to breast cancers.
When testing shows that a woman carries a bad gene, she has a much higher chance of getting breast cancer. These women usually then get more frequent MRIs, ultrasounds and mammograms to detect cancer.
Myriad owns the patent on breast cancer genes and so is the only company that can test for them. It offers one test that catches most, but not all, abnormalities, and then charges nearly all patients $700 for a second test that catches the rest.
If a woman can't afford the $700 fee, she may miss an abnormality, which could mean the difference between life and death.
Myriad defends the $700 charge for its second test, called BART, even though many patients can't afford it and insurance won't pay for it.